Alemtuzumab Treatment of Intermediate-1 Myelodysplasia Patients Is Associated With Sustained Improvement in Blood Counts and Cytogenetic Remissions

Journal of Clinical Oncology - United States
doi 10.1200/jco.2010.29.7010

Related search